We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Scancell Holdings Plc | LSE:SCLP | London | Ordinary Share | GB00B63D3314 | ORD 0.1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.10 | -1.03% | 9.65 | 9.30 | 10.00 | 9.75 | 9.65 | 9.75 | 542,863 | 10:14:22 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 5.27M | -11.94M | -0.0129 | -7.48 | 89.53M |
Date | Subject | Author | Discuss |
---|---|---|---|
23/1/2019 15:09 | To the BB If it's not obvious what happened just now, NXC (DE???) posted at 14.44 under the Name ALFTUPPER a message talking about why he hasn't posted before in relation to my earlier request when he said that he thought that sufficient time had passed that he could comment on Scancell without fear of affecting the current BOD position. That message was very quickly edited with all the text removed! Since NXC was supposedly the retiring Chairman DE I wonder why he didn't feel equally constrained on the Omega diagnostics BB on ADVFN where he'd been posting since October last when he stepped down in the same month. Since he posted today on here under AlfTupper I thought you'd enjoy a post (My 19013) from that version of DE nearly two years ago when he was being far from generous to the then BOD of Scancell. I'm not too certain that I'd like to endorse NXC or Alf Tupper as being DE in any shape or form. Should our erstwhile Chairman wish to make contact with ADVFN and they can then make contact with me to prove that he's both of these posters, I'll naturally withdraw my comments. looking forward to seeing what materialises. All In My Personal Opinion. ATB | oldnotwise | |
23/1/2019 14:56 | "alftupper17 May '17 - 17:07 - 9368 of 19012 0 1 0 Some perspective on the most successful fundraise ever. Given that two institutions came on board for the first time and they were classified as major institutions then their minimum ticket size would be £1m that then leaves £3m divided between 16 institutions = £187.5k each. The mark of success would not include a 42% discount to the last round of 13months ago. There is a disconnect here regarding timing - if there are significant value enhancing events coming soon why do the fundraise now - unless of course you are desperate." NXC Surely not the writing of an ex chairman nearly two years ago???? Alf, you should have posted your 19012 under NXS.... Bad error!!!!!!! ATB | oldnotwise | |
23/1/2019 14:24 | ONW, it does make you laugh doesn't it. Anyone with the slightest intelligence KNEW that CRUK were not putting £20 mill into the Scancell coffers. I argued this very point with the caped idiot on numerous occasions, but as always, even after being proven wrong, he will still never admit that he was wrong. Once again, people have been naive beyond belief, by listening to the idiot. I think it in very poor taste that the sheep are now rallying around and finding excuses as to why we were unsuccessful, eg ;- we didnt try - we didnt want it - maybe it was the American tie up - blah blah blah... All this does is prove just how STUPID they are, and detracts from the WINNERS of the GC, all of whom should be congratulated for winning, not undermined by idiots claiming that we let them have it.. Shame of you. | tosh 123 | |
23/1/2019 14:05 | I now notice that according to some the (illusive in the bag)GC award, " if Trinity's figure of 5% going to Scancell is close to correct, then yes, it is more trouble than it's worth. Perhaps, in the end, Scancell realised this and did not use too many resources pursuing GC." So now Scancell didn't bother too much! Bit of a dent in the lustrous promise that the GC was going to give Scancell £20m to add to its coffers...... And there was me thinking it was going to be massive for Scancell's future (the saviour of the SP). Sometimes less is probably more when you're in the pit with the spade..... AIMO ATB | oldnotwise | |
23/1/2019 13:57 | NXC Apols for pressing the issue but would you favour me with a reply to my 19004? Atb | oldnotwise | |
23/1/2019 13:44 | DE, I would like to join TF in passing on my best wishes. I was probably overly hard on you with a few of my posts a few years ago, and for that i unreservedly apologise. Most of the anger came from pent up frustrations that nothing appeared to be happening, and that the commercial element of the company seemed woefully inadequate ( it looks like the same can still be said ), coupled with the constant nondelivery. I wish you well sir,and thank you for taking the time and effort to clarify a few points, it is much appreciated. | tosh 123 | |
23/1/2019 13:36 | Thanks Lozan | nxc | |
23/1/2019 12:22 | NXC Thanks for your input this morning. If I may ask, what prompted you to suddenly start corresponding on a Scancell BB years after your departure? There have been many threads which would have benefitted from your inside knowledge for many years. Why start now? ATB | oldnotwise | |
23/1/2019 11:58 | If anyone is doubting my authenticity please refer to the ODX thread. The reason I do not post on the other Board is a question best answered by LSE admin. | nxc | |
23/1/2019 11:03 | NXC. Thank you for the insights. I hope you are keeping well. | torquayfan | |
23/1/2019 10:33 | Bermuda, have sent you a private message | panama7 | |
23/1/2019 10:01 | Thanks for the clarity NXC! | bermudashorts | |
23/1/2019 09:56 | Wonder if Holloway ( Goodfellow MK11 ) will do an interview on Proactive today. 3 Questions for him 1) What happened to the Monetisation of assets in the near term. 2) When is the 2016 Combi trial going to start . 3) How are you going to pay for your two expensive new recruits. | panama7 | |
23/1/2019 09:54 | As the former Chairman I can confirm that I was not prepared to split Moditope out of Scancell. The phrase Over My Dead Body springs to mind. My position was clear in seeking to protect Scancell Shareholders. The proposal was that a Newco be established with Lindy and Richard running it with new investment coming from a European based investor. The conflicts of interest in such a situation ( as Lindy and Richard were to remain at Scancell too) are obvious and ultimately unmanageable as you cannot dictate where people apply their effort when they are trying to ride two horses. My long experience of people riding two horses is that more often they slip off in between them. I felt the proposal was particularly unfair to existing Scancell Shareholders and economically incentivised the few not the many. As a wider observation " luck " exists in business and whilst the old Gary Player adage pertains Scancell have not been blessed with good luck - it is not an excuse but there is such a thin dividing line between success and failure and I have been on both sides of that line. At times it feels we are calling tails and the coin for the umpteenth time comes up heads. In fact not a dis-similar situation to our initial patient recruitment where the first nine patients were all the wrong HLA type - you could not make it up. I have supported two of the last three funding rounds ( the one I didn't was because I was not asked) and I believe that through sheer perseverance and the underlying quality of the science that sufficient data will be produced to convince others to make the investment necessary. The appointments on Monday help enormously in demonstrating that Scancell is a Company and not just a single person. That may help the bigger corporate's with their investment decision making. | nxc | |
23/1/2019 09:51 | Tosh, The rationale behind splitting off Moditope into a new company was that it would be easier to raise seed funding for a new discovery than to raise follow-on funding for existing company. Unfortunately that ship has sailed. I see where you're coming from but not sure the likes of BioNtech or Genentech would bother when they could very easily simply license Moditope or buy Scancell and own IP outright. | bermudashorts | |
23/1/2019 09:28 | I think RG was right! whoever it was, Inanoco got the other in a corner after the AGM and convinced him that Scancell could become the biggest, most profitable pharmaceutical company in the world and next year, Richard/David, we'll all be trillionaires. | gazza | |
23/1/2019 09:28 | ONW, i may well have it the wrong way round and it might have been RG that made the comment rather than DE ( the grey matter is not what it was, and its a few years ago now ). Whoever it was, the last 5 - 6 years seem to bear out their thoughts on the matter. Lets hope there is a plan B and that its nearly ready for announcement. The 2 new recruits were a massive warning sign for me that the GC wasn't going as well as the prawns on the other site were saying, it just didnt make sense. I also hope that there will be people who will finally appreciate what an oaf a certain person is. Its time for a reality check for quite a few people. This is a risky business, risks that cannot be mitigated by an uneducated idiot and a few cut n paste articles. | tosh123 | |
23/1/2019 09:08 | Tosh interesting comment in your 18990, but the DE reference you make goes somewhat against the RG comment that DE was against splitting the company post Moditope discovery. I still believe that that was probably the biggest missed opportunity to efficiently commercialise the SCLP IP. However in the Grand scale of things, who knows? ATB | oldnotwise | |
23/1/2019 09:05 | I think DE was right! | gazza | |
23/1/2019 09:01 | Heres an idea, not saying that it will happen, but its maybe a possibility. Modi will be hived off into a separate collaboration company with a third party / parties, who will fund the research and trials eg ;- the project blue print team. The new company will be part owned by all the collaborators ( including Scancell ). The SCIB technology will remain 100% owned by Scancell. From memory, i think it was DE who stated many years ago, that we were spreading ourselves too thinly, and should focus our efforts on one platform rather than trying to develop numerous. | tosh123 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions